DOI: 10.1007/978-1-60761-786-0_16. Oncolytic HSV as a Vector in Cancer Immunotherapy

Oncolytic HSV as a Vector in Cancer Immunotherapy

10.1007/978-1-60761-786-0_16

Crossref book-chapter

Humana Press

Methods in Molecular Biology (297)

Authors 2

Hongtao Li (first)
Xiaoliu Zhang (additional)

References 17 Referenced 5

Weiner, L. M. (2008) Cancer immunotherapy – the endgame begins. N Engl J Med 358, 2664–2665. (10.1056/NEJMp0803663) / N Engl J Med by L. M. Weiner (2008)
Waldmann, T. A. (2003) Immunotherapy: past, present and future. Nat Med 9, 269–277. (10.1038/nm0303-269) / Nat Med by T. A. Waldmann (2003)
Russell, S. J., and Peng, K. W. (2007) Viruses as anticancer drugs. Trends Pharmacol Sci 28, 326–333. (10.1016/j.tips.2007.05.005) / Trends Pharmacol Sci by S. J. Russell (2007)
Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P., Parish, I. A., Davey, G. M., Wilson, N. S., Carbone, F. R., and Villadangos, J. A. (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199, 9–26. (10.1111/j.0105-2896.2004.00142.x) / Immunol Rev by W. R. Heath (2004)
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S., and Zitvogel, L. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7, 297–303. (10.1038/85438) / Nat Med by J. Wolfers (2001)
Todo, T. (2008) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 13, 2060–2064. (10.2741/2823) / Front Biosci by T. Todo (2008)
Varghese, S., and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9, 967–978. (10.1038/sj.cgt.7700537) / Cancer Gene Ther by S. Varghese (2002)
Randazzo, B. P., Kesari, S., Gesser, R. M., Alsop, D., Ford, J. C., Brown, S. M., Maclean, A., and Fraser, N. W. (1995) Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94–101. (10.1006/viro.1995.1382) / Virology by B. P. Randazzo (1995)
Wong, R. J., Kim, S. H., Joe, J. K., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193, 12–21. (10.1016/S1072-7515(01)00866-3) / J Am Coll Surg by R. J. Wong (2001)
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938–943. (10.1038/nm0995-938) / Nat Med by T. Mineta (1995)
Wong, R. J., Patel, S. G., Kim, S., DeMatteo, R. P., Malhotra, S., Bennett, J. J., St-Louis, M., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12, 253–265. (10.1089/10430340150218396) / Hum Gene Ther by R. J. Wong (2001)
Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006) Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12, 643–652. (10.1158/1078-0432.CCR-05-1494) / Clin Cancer Res by Y. Ino (2006)
Li, H., Zeng, Z., Fu, X., and Zhang, X. (2007) Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res 67, 7850–7855. (10.1158/0008-5472.CAN-07-1087) / Cancer Res by H. Li (2007)
Li, H., Dutuor, A., Fu, X., and Zhang, X. (2007) Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 9, 161–169. (10.1002/jgm.1005) / J Gene Med by H. Li (2007)
Li, H., Dutuor, A., Tao, L., Fu, X., and Zhang, X. (2007) Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13, 316–322. (10.1158/1078-0432.CCR-06-1625) / Clin Cancer Res by H. Li (2007)
Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M. K., and Zhang, X. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 7, 748–754. (10.1016/S1525-0016(03)00092-3) / Mol Ther by X. Fu (2003)
Fu, X., Tao, L., Cai, R., Prigge, J., and Zhang, X. (2006) A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 13, 882–890. (10.1016/j.ymthe.2006.02.007) / Mol Ther by X. Fu (2006)

Dates

Type	When
Created	15 years ago (Aug. 4, 2010, 3:15 p.m.)
Deposited	6 years, 5 months ago (March 17, 2019, 11:26 a.m.)
Indexed	11 months, 3 weeks ago (Sept. 5, 2024, 2:57 p.m.)
Issued	15 years, 8 months ago (Jan. 1, 2010)
Published	15 years, 8 months ago (Jan. 1, 2010)
Published Online	15 years ago (Aug. 3, 2010)
Published Print	15 years, 8 months ago (Jan. 1, 2010)

Funders 0

None

BibTeX

@inbook{Li_2010, title={Oncolytic HSV as a Vector in Cancer Immunotherapy}, ISBN={9781607617860}, ISSN={1940-6029}, url={http://dx.doi.org/10.1007/978-1-60761-786-0_16}, DOI={10.1007/978-1-60761-786-0_16}, booktitle={Immunotherapy of Cancer}, publisher={Humana Press}, author={Li, Hongtao and Zhang, Xiaoliu}, year={2010}, pages={279–290} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2024,
        9,
        5
      ]
    ],
    "date-time": "2024-09-05T18:57:03Z",
    "timestamp": 1725562623923
  },
  "publisher-location": "Totowa, NJ",
  "reference-count": 17,
  "publisher": "Humana Press",
  "isbn-type": [
    {
      "type": "print",
      "value": "9781607617853"
    },
    {
      "type": "electronic",
      "value": "9781607617860"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2010
      ]
    ]
  },
  "DOI": "10.1007/978-1-60761-786-0_16",
  "type": "book-chapter",
  "created": {
    "date-parts": [
      [
        2010,
        8,
        4
      ]
    ],
    "date-time": "2010-08-04T19:15:43Z",
    "timestamp": 1280949343000
  },
  "page": "279-290",
  "source": "Crossref",
  "is-referenced-by-count": 5,
  "title": "Oncolytic HSV as a Vector in Cancer Immunotherapy",
  "prefix": "10.1007",
  "author": [
    {
      "given": "Hongtao",
      "family": "Li",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Xiaoliu",
      "family": "Zhang",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "published-online": {
    "date-parts": [
      [
        2010,
        8,
        3
      ]
    ]
  },
  "reference": [
    {
      "key": "16_CR1",
      "doi-asserted-by": "publisher",
      "first-page": "2664",
      "DOI": "10.1056/NEJMp0803663",
      "volume": "358",
      "author": "L. M. Weiner",
      "year": "2008",
      "unstructured": "Weiner, L. M. (2008) Cancer immunotherapy \u2013 the endgame begins. N Engl J Med\n                358, 2664\u20132665.",
      "journal-title": "N Engl J Med"
    },
    {
      "key": "16_CR2",
      "doi-asserted-by": "publisher",
      "first-page": "269",
      "DOI": "10.1038/nm0303-269",
      "volume": "9",
      "author": "T. A. Waldmann",
      "year": "2003",
      "unstructured": "Waldmann, T. A. (2003) Immunotherapy: past, present and future. Nat Med\n                9, 269\u2013277.",
      "journal-title": "Nat Med"
    },
    {
      "key": "16_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "326",
      "DOI": "10.1016/j.tips.2007.05.005",
      "volume": "28",
      "author": "S. J. Russell",
      "year": "2007",
      "unstructured": "Russell, S. J., and Peng, K. W. (2007) Viruses as anticancer drugs. Trends Pharmacol Sci\n                28, 326\u2013333.",
      "journal-title": "Trends Pharmacol Sci"
    },
    {
      "key": "16_CR4",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "DOI": "10.1111/j.0105-2896.2004.00142.x",
      "volume": "199",
      "author": "W. R. Heath",
      "year": "2004",
      "unstructured": "Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P., Parish, I. A., Davey, G. M., Wilson, N. S., Carbone, F. R., and Villadangos, J. A. (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev\n                199, 9\u201326.",
      "journal-title": "Immunol Rev"
    },
    {
      "key": "16_CR5",
      "doi-asserted-by": "publisher",
      "first-page": "297",
      "DOI": "10.1038/85438",
      "volume": "7",
      "author": "J. Wolfers",
      "year": "2001",
      "unstructured": "Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S., and Zitvogel, L. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med\n                7, 297\u2013303.",
      "journal-title": "Nat Med"
    },
    {
      "key": "16_CR6",
      "doi-asserted-by": "publisher",
      "first-page": "2060",
      "DOI": "10.2741/2823",
      "volume": "13",
      "author": "T. Todo",
      "year": "2008",
      "unstructured": "Todo, T. (2008) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci\n                13, 2060\u20132064.",
      "journal-title": "Front Biosci"
    },
    {
      "key": "16_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "967",
      "DOI": "10.1038/sj.cgt.7700537",
      "volume": "9",
      "author": "S. Varghese",
      "year": "2002",
      "unstructured": "Varghese, S., and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther\n                9, 967\u2013978.",
      "journal-title": "Cancer Gene Ther"
    },
    {
      "key": "16_CR8",
      "doi-asserted-by": "publisher",
      "first-page": "94",
      "DOI": "10.1006/viro.1995.1382",
      "volume": "211",
      "author": "B. P. Randazzo",
      "year": "1995",
      "unstructured": "Randazzo, B. P., Kesari, S., Gesser, R. M., Alsop, D., Ford, J. C., Brown, S. M., Maclean, A., and Fraser, N. W. (1995) Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology\n                211, 94\u2013101.",
      "journal-title": "Virology"
    },
    {
      "key": "16_CR9",
      "doi-asserted-by": "publisher",
      "first-page": "12",
      "DOI": "10.1016/S1072-7515(01)00866-3",
      "volume": "193",
      "author": "R. J. Wong",
      "year": "2001",
      "unstructured": "Wong, R. J., Kim, S. H., Joe, J. K., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg\n                193, 12\u201321.",
      "journal-title": "J Am Coll Surg"
    },
    {
      "key": "16_CR10",
      "doi-asserted-by": "publisher",
      "first-page": "938",
      "DOI": "10.1038/nm0995-938",
      "volume": "1",
      "author": "T. Mineta",
      "year": "1995",
      "unstructured": "Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med\n                1, 938\u2013943.",
      "journal-title": "Nat Med"
    },
    {
      "key": "16_CR11",
      "doi-asserted-by": "publisher",
      "first-page": "253",
      "DOI": "10.1089/10430340150218396",
      "volume": "12",
      "author": "R. J. Wong",
      "year": "2001",
      "unstructured": "Wong, R. J., Patel, S. G., Kim, S., DeMatteo, R. P., Malhotra, S., Bennett, J. J., St-Louis, M., Shah, J. P., Johnson, P. A., and Fong, Y. (2001) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther\n                12, 253\u2013265.",
      "journal-title": "Hum Gene Ther"
    },
    {
      "key": "16_CR12",
      "doi-asserted-by": "publisher",
      "first-page": "643",
      "DOI": "10.1158/1078-0432.CCR-05-1494",
      "volume": "12",
      "author": "Y. Ino",
      "year": "2006",
      "unstructured": "Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006) Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res\n                12, 643\u2013652.",
      "journal-title": "Clin Cancer Res"
    },
    {
      "key": "16_CR13",
      "doi-asserted-by": "publisher",
      "first-page": "7850",
      "DOI": "10.1158/0008-5472.CAN-07-1087",
      "volume": "67",
      "author": "H. Li",
      "year": "2007",
      "unstructured": "Li, H., Zeng, Z., Fu, X., and Zhang, X. (2007) Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res\n                67, 7850\u20137855.",
      "journal-title": "Cancer Res"
    },
    {
      "key": "16_CR14",
      "doi-asserted-by": "publisher",
      "first-page": "161",
      "DOI": "10.1002/jgm.1005",
      "volume": "9",
      "author": "H. Li",
      "year": "2007",
      "unstructured": "Li, H., Dutuor, A., Fu, X., and Zhang, X. (2007) Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med\n                9, 161\u2013169.",
      "journal-title": "J Gene Med"
    },
    {
      "key": "16_CR15",
      "doi-asserted-by": "publisher",
      "first-page": "316",
      "DOI": "10.1158/1078-0432.CCR-06-1625",
      "volume": "13",
      "author": "H. Li",
      "year": "2007",
      "unstructured": "Li, H., Dutuor, A., Tao, L., Fu, X., and Zhang, X. (2007) Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res\n                13, 316\u2013322.",
      "journal-title": "Clin Cancer Res"
    },
    {
      "key": "16_CR16",
      "doi-asserted-by": "publisher",
      "first-page": "748",
      "DOI": "10.1016/S1525-0016(03)00092-3",
      "volume": "7",
      "author": "X. Fu",
      "year": "2003",
      "unstructured": "Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M. K., and Zhang, X. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther\n                7, 748\u2013754.",
      "journal-title": "Mol Ther"
    },
    {
      "key": "16_CR17",
      "doi-asserted-by": "publisher",
      "first-page": "882",
      "DOI": "10.1016/j.ymthe.2006.02.007",
      "volume": "13",
      "author": "X. Fu",
      "year": "2006",
      "unstructured": "Fu, X., Tao, L., Cai, R., Prigge, J., and Zhang, X. (2006) A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther\n                13, 882\u2013890.",
      "journal-title": "Mol Ther"
    }
  ],
  "container-title": "Methods in Molecular Biology",
  "original-title": [],
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/978-1-60761-786-0_16",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2019,
        3,
        17
      ]
    ],
    "date-time": "2019-03-17T15:26:50Z",
    "timestamp": 1552836410000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "http://link.springer.com/10.1007/978-1-60761-786-0_16"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2010
      ]
    ]
  },
  "ISBN": [
    "9781607617853",
    "9781607617860"
  ],
  "references-count": 17,
  "URL": "http://dx.doi.org/10.1007/978-1-60761-786-0_16",
  "relation": {},
  "ISSN": [
    "1064-3745",
    "1940-6029"
  ],
  "subject": [],
  "published": {
    "date-parts": [
      [
        2010
      ]
    ]
  }
}